AAPG
Ascentage
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
AAPG Profile
Ascentage Pharma Group International
A Chinese based and globally oriented original new drug research and development enterprise
Pharmaceutical
11/17/2017
01/24/2025
NASDAQ Stock Exchange
567
12-31
Depository Receipts (Ordinary Shares)
68 Xinqing Road, Suzhou Industrial Park, Suzhou, Jiangsu, China
The company is a global integrated biopharmaceutical company engaged in the discovery, development and commercialization of first-of-its-kind and best-in-class therapies to address the global unmet medical needs of hematological malignancies.
Ascentage Pharmaceutical Group was established on November 17, 2017. Ascentage Pharma Group is an investment holding company principally engaged in the development of innovative micro-therapies for cancer, hepatitis B virus and certain aging-related diseases. The company has a self-developed protein-protein interaction targeted drug design platform. The company's main products include the next-generation kinase inhibitor HQP1351, apoptosis-targeting drugs APG-1252, APG2575, APG-115, etc. The company operates in the domestic market and overseas markets such as the United States.